Takeda Pharmaceutical (TAK) Total Non-Current Liabilities (2017 - 2026)

Takeda Pharmaceutical's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $33.5 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 6.25% year-over-year to $33.5 billion in Q1 2026; TTM through Mar 2026 was $33.5 billion, a 6.25% increase from a year earlier, with the FY2026 full-year figure at $34.9 billion, up 10.52% from the prior year.
• Total Non-Current Liabilities held at $33.5 billion in Q1 2026 per TAK's latest filing, from $33.5 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $46.0 billion in Q1 2022 and bottomed at $31.5 billion in Q1 2025.
• The 5-year median for Total Non-Current Liabilities is $36.8 billion (2024), against an average of $37.1 billion.
• Across the five-year window, Total Non-Current Liabilities retreated 26.29% in 2022 and climbed 6.25% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $36.0 billion in 2022, then dropped by 2.42% to $35.2 billion in 2023, then increased by 4.55% to $36.8 billion in 2024, then decreased by 8.91% to $33.5 billion in 2025, then fell by 0.07% to $33.5 billion in 2026.
• Per Business Quant, the three latest TAK Total Non-Current Liabilities figures stand at $33.5 billion (Q1 2026), $33.5 billion (Q4 2025), and $35.3 billion (Q3 2025).